Transdermal sumatriptan closer to marketing
This article was originally published in Scrip
Executive Summary
The private US company NuPathe plans to submit a US NDA next year for its novel iontophoretic sumatriptan patch, Zelrix. NuPathe expects Zelrix to be the first transdermal patch to be marketed for migraine.